Effects of once-weekly semaglutide vs canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 trial

被引：0
|
作者：
McCrimmon, R. J. [1 ]
Catarig, A. [2 ]
Frias, J. P. [3 ]
Lausvig, N. L. [2 ]
le Roux, C. W. [4 ]
Thielke, D. [2 ]
Lingvay, I. [5 ]
机构：
[1] Univ Dundee, Dundee, Scotland
[2] Novo Nordisk AS, Soborg, Denmark
[3] Natl Res Inst, Los Angeles, CA USA
[4] Univ Coll Dublin, Dublin, Ireland
[5] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
54
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [41] Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
    Kristin Cecilie Carlsson Petri
    Steen Hvass Ingwersen
    Anne Flint
    Jeppe Zacho
    Rune Viig Overgaard
    Diabetes Therapy, 2018, 9 : 1533 - 1547
  • [42] Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial
    Kolkailah, Ahmed A.
    Lingvay, Ildiko
    Dobrecky-Mery, Idit
    Aharonovich, Alona
    David, Jens-Peter
    Holse, Cecilie
    Rasmussen, Soren
    McGuire, Darren K.
    DIABETES OBESITY & METABOLISM, 2023, 25 (04): : 1117 - 1120
  • [43] Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
    Kaku, Kohei
    Yamada, Yuichiro
    Watada, Hirotaka
    Abiko, Atsuko
    Nishida, Tomoyuki
    Zacho, Jeppe
    Kiyosue, Arihiro
    DIABETES OBESITY & METABOLISM, 2018, 20 (05): : 1202 - 1212
  • [44] Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China
    Ji, Linong
    Lu, Yibing
    Shen, Zewei
    Hu, Ping
    Liu, Wenyan
    Zhang, Qiu
    Shi, Bimin
    DIABETES OBESITY & METABOLISM, 2024,
  • [45] Reduced glycaemic variability with once-weekly semaglutide vs active comparators in post hoc analysis of the SUSTAIN programme
    Jodar, E.
    Aroda, V. R.
    Kose, Y.
    Kaltoft, M.
    Sondergaard, A. L.
    Pratley, R.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 250 - 250
  • [46] Greater Proportions of Subjects Achieved Composite Endpoints with Once-Weekly Semaglutide vs. Comparators in SUSTAIN Trials
    Gaede, Peter
    Catarig, Andrei-Mircea
    Dungan, Kathleen M.
    Hindsberger, Charlotte
    Ollgaard, Jens
    Bain, Stephen C.
    DIABETES, 2021, 70
  • [47] Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA
    Silvio E. Inzucchi
    Xi Tan
    Yuanjie Liang
    Larisa Yedigarova
    Lin Xie
    Adam de Havenon
    Diabetes Therapy, 2025, 16 (2) : 187 - 203
  • [48] Efficacy and safety of once-weekly semaglutide in elderly subjects with type 2 diabetes: post hoc analysis of SUSTAIN 1-5 trials
    Warren, M.
    Chaykin, L.
    Trachtenbarg, D.
    Nayak, G.
    Wijayasinghe, N.
    Cariou, B.
    DIABETOLOGIA, 2017, 60 : S378 - S379
  • [49] Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
    Holman, Rury R.
    Bethel, M. Angelyn
    Mentz, Robert J.
    Thompson, Vivian P.
    Lokhnygina, Yuliya
    Buse, John B.
    Chan, Juliana C.
    Choi, Jasmine
    Gustavson, Stephanie M.
    Iqbal, Nayyar
    Maggioni, Aldo P.
    Marso, Steven P.
    Ohman, Peter
    Pagidipati, Neha J.
    Poulter, Neil
    Ramachandran, Ambady
    Zinman, Bernard
    Hernandez, Adrian F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (13): : 1228 - 1239
  • [50] Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
    Buse, John B.
    Christensen, Helene Nordahl
    Harty, Brian J.
    Mitchell, Julie
    Soule, Benjamin P.
    Zacherle, Emily
    Cziraky, Mark
    Willey, Vincent J.
    BMJ OPEN DIABETES RESEARCH & CARE, 2023, 11 (03)
12345